| Identification | Back Directory | [Name]
BAFILOMYCIN A1 | [CAS]
88899-55-2 | [Synonyms]
BAFILOMYCIN A1
BAFILOMYCIN A1 95%
Bafilomycin A1,95%
BAFILOMYCIN A1, 98+%
Bafilomycin A1(Baf-A1)
BafilomycinA1fromStreptomycesgriseus
BAFILOMYCIN A1, STREPTOMYCES GRISEUS
Bafilomycin A1 from Streptomycesgriseus, 10 ug
Bafilomycin A1 Bafilomycin A1 from Streptomyces griseus
21-O-de(3-carboxy-1-oxo-2-propenyl)-2-demethyl-2-methoxy-24-methyl-hygrolidin
(3Z,5E,7R,8S,9S,11E,13E,15S,16R)-8-Hydroxy-16-((1S,2R,3S)-2-hydroxy-1-methyl-3-((2R,4R,5S,6R)-tetrahydro-2,4-dihydroxy-5
(3Z,5E,7R,8S,9S,11E,13E,15S,16R)-8-Hydroxy-16-[(1S,2R,3S)-2-hydroxy-1-Methyl-3-[(2R,4R,5S,6R)-tetrahydro-2,4-dihydroxy-5-Methyl-6-(1-Methylethyl)-2H-pyran-2-yl]butyl]-3,15-diMethoxy-5,7,9,11-tetraMethyloxacyclohexadeca-3,5,11,13-tetraen-2-o
(3Z,5E,7R,8S,9S,11E,13E,15S,16R)-8-Hydroxy-16-[(1S,2R,3S)-2-hydroxy-1-methyl-3-[(2R,4R,5S,6R)-tetrahydro-2,4-dihydroxy-5-methyl-6-(1-methylethyl)-2H-pyran-2-yl]butyl]-3,15-dimethoxy-5,7,9,11-tetramethyloxacyclohexadeca-3,5,11,13-tetraen-2-one | [EINECS(EC#)]
621-324-4 | [Molecular Formula]
C35H58O9 | [MDL Number]
MFCD06795130 | [MOL File]
88899-55-2.mol | [Molecular Weight]
622.83 |
| Chemical Properties | Back Directory | [Appearance]
white to off-white powder | [Melting point ]
>106°C (dec.) | [Boiling point ]
582.86°C (rough estimate) | [density ]
1.0594 (rough estimate) | [refractive index ]
1.5000 (estimate) | [RTECS ]
RN9781000 | [Fp ]
87℃ | [storage temp. ]
2-8°C
| [solubility ]
Soluble in DMSO (up to 5 mg/ml, with warming). | [form ]
Powder or Solid | [pka]
12.66±0.70(Predicted) | [color ]
White to off-white | [biological source]
Streptomyces griseus | [Water Solubility ]
Soluble in methanol, ethanol, acetone and chloroform. Insoluble in water. | [BRN ]
4730700 | [Stability:]
Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| Hazard Information | Back Directory | [Chemical Properties]
white to off-white powder | [Uses]
A macrolide antibiotic and potent and selective inhibitor of vacuolar-type (v-type) H+ ATPase | [Uses]
Bafilomycin A1 is a member of a potent family of macrocyclic lactones with broad spectrum biological activity, including activity against bacteria, yeast, fungi, nematodes, insects and tumor cell lines. Bafilomycin A1 is an inhibitor of vacuolar-type ATPase. | [Uses]
Bafilomycin A1 is a member of a potent family of macrocyclic lactones with broad spectrum biological activity, including activity against bacteria, yeast, fungi, nematodes, insects and tumour cell lines. Bafilomycin A1 is an inhibitor of vacuolar-type ATPase. | [Definition]
ChEBI: The most used of the bafilomycins, a family of toxic macrolide antibiotics derived from Streptomyces griseus. | [Biological Activity]
Highly potent, selective inhibitor of vacuolar H + -ATPases (IC 50 = 500 pM as measured in chromaffin granule membranes). Selective over other ATP hydrolyzing enzymes such as F-ATPases, Ca 2+ -ATPases, Na + /K + -ATPases and plasma membrane H + -ATPases. | [Description]
Bafilomycin A1 is a fungal metabolite that has been found in Streptomyces and has diverse biological activities.1,2,3,4,5 It is an inhibitor of vacuolar H+-ATPases (V-ATPases; Ki = 0.5 nM in N. crassa vacuolar membranes) and is greater than 1,000-fold selective for V-ATPases over Na+/K+-, Ca2+-, and H+-ATPases.1,4 Bafilomycin A1 (100 nM) inhibits autophagosome maturation and protein degradation in H-4-II-E cells.2 It inhibits chloroquine-induced apoptosis in primary cerebellar granule neurons (CGNs) but not chloroquine-induced inhibition of macroautophagy.3 Bafilomycin A1 (100 nM) reduces viral yield in the culture supernatant of Vero E6 and Huh7 cells, as well as HEK293T cells expressing human angiotensin-converting enzyme 2 (ACE2), infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).5 It also reduces lung RNA copy numbers and viral pneumonia in ACE2 transgenic mice infected with SARS-CoV-2 when administered at a dose of 0.1 mg/kg. | [General Description]
A macrolide antibiotic that acts as a specific inhibitor of vacuolar-type H+-ATPase (V-type; Ki = 500 pM). A valuable tool for distinguishing among different types of ATPases. Blocks lysosomal cholesterol trafficking in macrophages and is known to interfere with pH regulation in brain cells. Exhibits cytotoxic effects on a number of cell lines in a cell viability assay. Reported to selectively inhibit β-secretase, an enzyme involved in the processing of amyloid precursor protein (APP). The InSolution format with a purity of ≥97% by HPLC in 90% DMSO is also available (Cat. No. 508409). | [Biochem/physiol Actions]
Bafilomycin A1 is a macrolide antibiotic. Bafilomycin A1 acts as a potent and selective inhibitor of vacuolar-type H+-ATPase. | [storage]
Desiccate at -20°C, protect from light | [References]
1) Werner?et al.? (1984) Metabolic products of microorganisms. Bafilomycins, a new group of macrolide antibiotics. Production, isolation, chemical structure and biological activity; J. Antibiot.,?37?110
2) Drose and Altendorf? (1997)?Bafilomycins and concanamycins as inhibitors of V-ATPase and P-ATPase;?J. Exp. Biol.,?200?1
3) Yamamoto?et al. (1998)?Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells;?Cell Struct. Func.,?23?33 |
|
|